Residency · Residency · Child Adolescent Psychiatry

Screening and Assessment for Adolescent Substance Use

Overview

Substance use is remarkably common during adolescence. By the time they reach twelfth grade, approximately half of all adolescents have tried alcohol, roughly 35% have used cannabis, and about 20% have vaped nicotine. Adolescent substance use exists along a spectrum that ranges from one-time experimentation all the way to a diagnosable substance use disorder, and most young people who experiment never progress to clinical addiction. However, early and heavy use are among the most potent risk factors for later substance use disorders. The CRAFFT screening tool is the most widely validated brief instrument for identifying problematic use in this age group. Motivational interviewing is the primary evidence-based approach for brief intervention, and confidentiality considerations are central to obtaining honest disclosure from adolescent patients. The adolescent brain's ongoing neurodevelopment makes it uniquely vulnerable to the effects of substances, which underscores the importance of early identification and intervention.

Epidemiology

Alcohol remains the most commonly used substance among adolescents, although use rates have been declining in recent years. Cannabis use has held relatively steady or increased, and the products available today are significantly more potent than those of previous decades. Vaping of both nicotine and cannabis has risen dramatically since 2017. Opioid misuse among adolescents has actually decreased overall, but the introduction of illicit fentanyl into the drug supply has made any opioid use far more dangerous, sharply increasing overdose fatality risk. Polysubstance use is common and amplifies risk. Disparities in substance use rates exist across race, ethnicity, socioeconomic status, and geography, with LGBTQ+ youth consistently showing higher rates than their heterosexual peers.

Spectrum of Adolescent Substance Use

Adolescent substance involvement spans several levels. At one end is complete abstinence. Experimentation describes trying a substance once or twice, typically in a social setting and driven by curiosity. Regular use involves repeated substance use that does not yet meet criteria for a disorder and is often social or situational. Problematic use causes functional impairment such as academic decline, relationship problems, or increased risk-taking but may not fulfill the full diagnostic threshold. A substance use disorder, as defined by the DSM-5, requires two or more of eleven specified symptoms over a twelve-month period, and it is classified as mild (two to three symptoms), moderate (four to five), or severe (six or more). Although most adolescents who experiment never progress to a disorder, certain risk factors significantly increase the likelihood of escalation.

Risk and Protective Factors

Risk Factors

Several factors increase an adolescent's likelihood of progressing along the substance use spectrum. Early age of first use, particularly before age fourteen, is one of the strongest predictors of later substance use disorder. A family history of addiction carries both genetic and environmental risk. Comorbid psychiatric disorders, including ADHD, conduct disorder, depression, anxiety, and PTSD, substantially raise vulnerability. Peer substance use is the most powerful proximal predictor of an adolescent's own use. Childhood trauma and adverse childhood experiences, poor academic engagement and school failure, an impulsive and sensation-seeking temperament, and ready availability of substances all contribute additional risk.

Protective Factors

On the protective side, strong family bonds and effective parental monitoring reduce substance use risk. Academic engagement and a sense of connection to school are protective, as is involvement in prosocial activities such as sports, arts, and community organizations. Religious or spiritual involvement, positive peer relationships, and access to mental health treatment for comorbid conditions all serve as buffers against substance misuse.

Screening

CRAFFT Screening Tool

The CRAFFT is the most widely validated and recommended screening instrument for adolescent substance use, designed for individuals aged twelve to twenty-one. The updated version, CRAFFT 2.1, includes vaping-specific questions. The tool has a two-part structure. Part A consists of frequency questions about past-twelve-month use of alcohol, cannabis, and other substances, including vaping. If any use is endorsed, Part B follows with six questions: whether the adolescent has ridden in a Car driven by someone who was high or using substances; whether they use substances to Relax, feel better, or fit in; whether they use Alone; whether they Forget things they did while using; whether Family or Friends have told them to cut down; and whether they have gotten into Trouble while using. A score of two or more on the CRAFFT questions suggests problematic use warranting further assessment. The tool is free, validated in multiple languages, and recommended by the American Academy of Pediatrics for universal adolescent screening.

Other Screening Tools

Several other validated instruments exist. The S2BI (Screening to Brief Intervention) is a frequency-based screen that categorizes risk level based on how often substances are used. The BSTAD (Brief Screener for Tobacco, Alcohol, and Other Drugs), developed by NIDA, is another brief frequency-based option. The AUDIT (Alcohol Use Disorders Identification Test) is validated for adolescents specifically for alcohol screening. The TAPS (Tobacco, Alcohol, Prescription medications, and other Substance use tool) provides a comprehensive screen across substance categories.

Universal Screening Recommendations

The AAP recommends universal substance use screening starting at age eleven. Screening should occur at annual well-child visits and at any clinical encounter where substance use may be relevant. The recommended approach is to begin with frequency questions, and if use is endorsed, follow up with the full CRAFFT. Substance use screening is most effective when embedded within a broader psychosocial assessment, such as the HEEADSSS framework.

Comprehensive Assessment

Clinical Interview

A thorough clinical interview begins with building rapport and assuring confidentiality, with clearly stated limits, before asking about substance use. Non-judgmental, normalizing language is essential. Clinicians should assess all major substance categories, including alcohol, cannabis, nicotine and vaping, prescription drugs (stimulants, opioids, benzodiazepines), hallucinogens, and inhalants. For each substance endorsed, the clinician should determine age of first use, frequency, quantity, route of administration, context of use, and progression over time. Functional impairment should be carefully assessed, including academic decline, relationship problems, legal issues, and risky behaviors such as driving under the influence or unprotected sex. Screening for DSM-5 substance use disorder criteria, including tolerance, withdrawal, loss of control, craving, and continued use despite consequences, is essential. Comorbid psychiatric conditions, particularly ADHD, depression, anxiety, PTSD, and conduct disorder, must be assessed because they are extremely common among adolescents with substance use problems. Suicidality should always be evaluated, as substance use significantly increases suicide risk.

Laboratory Testing

Urine drug screens can be useful for confirming or monitoring substance use, though they have limitations including variable detection windows and the possibility of false negatives. Standard immunoassay panels may not detect synthetic cannabinoids, fentanyl, or certain novel substances. Ethyl glucuronide, a urine marker, can detect recent alcohol use. Drug testing should be discussed openly with the adolescent and framed as a clinical tool rather than a punitive measure. It is never a substitute for a thorough clinical assessment.

Confidentiality Considerations

Adolescents are significantly more likely to disclose substance use honestly if they are assured of confidentiality. Minor consent laws vary by state, and many jurisdictions allow minors to consent independently for substance use treatment. Best practice is to establish a confidentiality agreement at the beginning of treatment, clearly explaining what will and will not be shared with parents. Safety exceptions -- imminent danger to self or others, abuse, and severe intoxication -- should be spelled out explicitly. Clinicians should encourage adolescents to involve their parents voluntarily when appropriate. General information can be shared with parents without revealing specific substance use details, unless safety concerns require full disclosure. All confidentiality discussions should be clearly documented.

Brief Intervention: SBIRT Model

Screening, Brief Intervention, and Referral to Treatment (SBIRT)

SBIRT is an evidence-based public health framework for addressing substance use across the severity spectrum. The screening component uses the CRAFFT or another validated tool. Brief intervention is designed for those who screen positive but do not necessarily meet criteria for a substance use disorder, and it is grounded in motivational interviewing principles. Referral to treatment is indicated for adolescents who meet substance use disorder criteria or show severe use patterns.

Motivational Interviewing (MI) with Adolescents

Motivational interviewing is the most evidence-based brief intervention approach for adolescent substance use. Its core principles are expressing empathy, developing discrepancy between current behavior and personal goals, rolling with resistance rather than confronting it, and supporting self-efficacy. When used with adolescents, MI is adapted to be shorter, more interactive, and less confrontational. The approach acknowledges the adolescent's autonomy and developmental need for independence. Rather than imposing adult concerns, the clinician explores the adolescent's own reasons for considering change. Decisional balance exercises, which explore what the adolescent perceives as both positive and negative about their use, are particularly effective. Evidence demonstrates that even a single MI session can reduce substance use in at-risk adolescents.

<image>A flowchart showing the SBIRT (Screening, Brief Intervention, Referral to Treatment) model adapted for adolescents. Start with universal screening (CRAFFT 2.1). If no use: positive reinforcement, anticipatory guidance. If lower-risk use (CRAFFT score 0-1): brief advice, education, re-screen at next visit. If higher-risk use (CRAFFT score 2+): brief motivational intervention, assess for SUD, follow-up. If SUD criteria met or severe use: referral to specialized adolescent substance use treatment. Show the CRAFFT questions in a callout box.</image>

<image>A spectrum diagram showing the continuum of adolescent substance use from abstinence through experimentation, regular use, problematic use, to substance use disorder. At each point on the spectrum, show the appropriate intervention: positive reinforcement and prevention (abstinence), brief education (experimentation), brief motivational intervention (regular use), comprehensive assessment and outpatient treatment (problematic use), specialized SUD treatment including possible medication-assisted treatment (SUD). Include risk factors that increase progression along the spectrum.</image>

<image>An infographic on confidentiality in adolescent substance use assessment. Show a balance scale weighing adolescent confidentiality (promotes disclosure, builds trust, legally protected in many states) against safety concerns (imminent danger, abuse, severe intoxication). Include a sample confidentiality statement that clinicians can use with adolescents and families. Show the recommended approach: establish confidentiality agreement early, encourage voluntary parental involvement, break confidentiality only for safety.</image>

Clinical Pearls

Early age of first substance use, particularly before age fourteen, is one of the strongest predictors of developing a substance use disorder, making prevention and early intervention critical. The CRAFFT is free, validated, takes two to three minutes, and should be used for universal screening starting at age eleven. Confidentiality is essential for honest disclosure, and the confidentiality framework should be explicitly established at the start of each clinical encounter. Motivational interviewing is more effective than confrontational approaches, and clinicians should avoid lecturing or moralizing. Comorbid psychiatric conditions should always be screened for, as most adolescents with substance use disorders have at least one co-occurring disorder, particularly ADHD, depression, PTSD, and conduct disorder. Substance use in adolescents often serves a coping function, such as managing anxiety, social discomfort, or trauma symptoms, and addressing the underlying driver is essential. Peer substance use is the strongest proximal risk factor, so understanding the adolescent's social context is critical. Urine drug screens are a clinical tool, not a punitive measure, and should be discussed openly with the adolescent, obtaining assent when possible.

References

• Knight, J.R. et al. (2002). Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Archives of Pediatrics & Adolescent Medicine, 156(6), 607-614.
• Levy, S.J. & Williams, J.F. (2016). Substance use screening, brief intervention, and referral to treatment. Pediatrics, 138(1), e20161211.
• Jensen, C.D. et al. (2011). Effectiveness of motivational interviewing for adolescent substance use behavior change: a meta-analysis. Journal of Consulting and Clinical Psychology, 79(4), 433-440.
• Winters, K.C. et al. (2011). Adolescent substance abuse treatment: a review of evidence-based research. AACAP Committee on Substance Abuse. Practice parameter for adolescent SUD.
• Substance Abuse and Mental Health Services Administration (SAMHSA). (2020). Key substance use and mental health indicators.
• Johnston, L.D. et al. (2023). Monitoring the Future national survey results. University of Michigan.

Read this lecture as Markdown